Safety and immunogenicity of COVID-19 mRNA vaccine SYS6006 evaluated in Phase 1 trial

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 600 million confirmed cases and 6.5 million deaths worldwide. mRNA-based vaccines have emerged as a leading platform for COVID-19 protection and are extensively investigated in basic and clinical trials.

Leave A Comment

Your email address will not be published. Required fields are marked *